Cushing’s Syndrome (CS) – Market Outlook, Epidemiology, Competitive Landscape, and Market Forecast Report – 2024 To 2034

Cushing’s Syndrome (CS) Market Outlook

Thelansis’s “Cushing’s Syndrome (CS) Market Outlook, Epidemiology, Competitive Landscape, and Market Forecast Report – 2024 To 2034" covers disease overview, epidemiology, drug utilization, prescription share analysis, competitive landscape, clinical practice, regulatory landscape, patient share, market uptake, market forecast, and key market insights under the potential Cushing’s Syndrome (CS) treatment modalities options for eight major markets (USA, Germany, France, Italy, Spain, UK, Japan, and China).

Cushing’s Syndrome (CS) Overview

Cushing’s Disease (CD), the leading cause of endogenous Cushing’s Syndrome (CS), results from the persistent overproduction of ACTH by a pituitary corticotroph adenoma. CD predominantly affects females, with a female-to-male ratio of 4-5:1, except in prepubertal patients, where males are more commonly affected. The peak age of onset occurs between 25 and 40 years. CD symptoms include typical CS features like central obesity, facial rounding, hypercatabolism signs, skin hyperpigmentation, and, in some cases, corticotroph macro-adenoma, neurological complications. Cushing’s syndrome can present with varying signs and symptoms. Prolonged exposure to elevated cortisol levels leads to evident manifestations such as weight gain, thin extremities, a rounded face, fat accumulation around the neck, a fatty hump between the shoulders, easy bruising, wide purple stretch marks, mainly on the abdomen, breasts, hips, and under the arms, and muscle weakness. The exact pathogenesis of pituitary tumors remains largely unknown. Most pituitary adenomas are sporadic, although a small percentage (<5%) occur within familial syndromes like multiple endocrine neoplasia type 1 (MEN 1), caused by MEN1 gene mutations (11q13), familial isolated pituitary adenomas (FIPA), where 15% of patients have AIP gene mutations (11q13-32), and the recently described multiple endocrine neoplasia type 4 (MEN 4), linked to CDKN1B gene mutations. Endogenous Cushing’s syndrome is traditionally classified as ACTH-dependent or ACTH-independent. ACTH-dependent cases account for 80%-85% of all instances. Among these, approximately 75%-80% stem from pituitary adenomas (Cushing’s Disease or CD), 15%-20% from nonpituitary tumors (ectopic ACTH syndrome or EAS), and less than 1% from corticotropin-releasing hormone (CRH)-producing tumors. Most pituitary tumors arise sporadically, originating from a single mutated cell. Surgical removal of the source of excess glucocorticoids, whether a pituitary adenoma, nonpituitary ACTH-secreting tumor, or adrenal tumor(s), is the primary treatment for all forms of Cushing’s syndrome. Transsphenoidal surgery yields an initial remission rate of 60%-80% (less than 15% in macroadenomas) with a relapse rate of up to 20% within a decade.

 

Geography coverage:

G8 (United States, EU5 [France, Germany, Italy, Spain, U.K.], Japan, and China)

Insights driven by robust research, including:

• In-depth interviews with leading KOLs and payers
• Physician surveys
• RWE analysis for claims and EHR datasets
• Secondary research (e.g., peer-reviewed journal articles, third-party research databases)

Deliverables format and updates*:

• Detailed Report (PDF)
• Market Forecast Model (MS Excel-based automated dashboard)
• Epidemiology (MS Excel; interactive tool)
• Executive Insights (PowerPoint presentation)
• Others: regular updates, customizations, consultant support

*As per Thelansis’s policy, we ensure that we include all the recent updates before releasing the report content and market model.

Salient features of Market Forecast model:

• 10-year market forecast (2024–2034)
• Bottom-up patient-based market forecasts validated through the top-down sales methodology
• Covers clinically and commercially-relevant patient populations/ line of therapies
• Annualized drug-level sales and patient share projections
• Utilizes our proprietary Epilansis and Analog tool (e.g., drug uptake and erosion) datasets and conjoint analysis approach
• Detailed methodology/sources &amp; assumptions
• Graphical and tabular outputs
• Users can customize the model based on requirements

Key business questions answered:

• How can drug development and lifecycle management strategies be optimized across G8 markets (US, EU5, Japan, and China)?
• How large is the patient population in terms of incidence, prevalence, segments, and those receiving drug treatments?
• What is the 10-year market outlook for sales and patient share?
• Which events will have the greatest impact on the market’s trajectory?
• What insights do interviewed experts provide on current and emerging treatments?
• Which pipeline products show the most promise, and what is their potential for launch and future positioning?
• What are the key unmet needs and KOL expectations for target profiles?
• What key regulatory and payer requirements must be met to secure drug approval and favorable market access?
• and more…

Read more: Cushing’s Syndrome (CS) – Market Outlook, Epidemiology, Competitive Landscape, and Market Forecast Report – 2024 To 2034